Status message

Active context: kki_bg_colors_yellow

A 6-Week, Randomized, Multicenter, Double-Blind, Parallel, Flexed- and Fixed-Dose Study Of Mg01ci (Metadoxine Extended-Release) 700 Mg and 1400 Mg Compared With Placebo in Adults and Adolescents With Fragile X Syndrome

Principal Investigator:
Robert
Findling

The study medication, MG01CI (Metadoxine Immediate-release/Slow-release Bilayer Tablet), is being investigated for the treatment of Fragile X Syndrome (FXS) in adults and adolescents. The purpose of this clinical study is to study how well MG01CI (Metadoxine immediate-release/slow-release, bilayer tablet) 700 mg and 1400 mg daily works compared with placebo in the treatment of symptoms of FXS, such as attention deficit hyperactivity disorder (ADHD) and other cognitive symptoms, in adults and adolescents.

Kennedy Krieger Institute Announces Retirement of President and CEO

Dr. Gary W. GoldsteinThe Institute’s board of directors is conducting a national search and is expected to name a new CEO in the coming months.
Learn more.

Publications

Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.